Filing Flows › Comparisons › CTOR vs ACRS
Citius Oncology vs Aclaris Therapeutics: CTOR and ACRS compared
Citius Oncology is the larger company: $1.5M of revenue in its latest quarter (Q3 FY26) against $1.5M for Aclaris Therapeutics (Q3 2026).
Where the money goes: CTOR and ACRS
Citius Oncology (CTOR) · Q3 FY26
Citius Oncology, Q3 FY26: revenue $1.5M, operating margin -583.5%, net loss $8.9M, operating cash flow −$2.7M. The chart follows the revenue to costs, profit and cash.
Aclaris Therapeutics (ACRS) · Q3 2026
Aclaris Therapeutics, Q3 2026: revenue $1.5M (-55% year over year), net loss $18.5M, operating cash flow −$24.1M. The chart follows the revenue to costs, profit and cash.
| Citius Oncology (CTOR) | Aclaris Therapeutics (ACRS) | |
|---|---|---|
| Latest quarter | Q3 FY26 | Q3 2026 |
| Revenue | $1.5M | $1.5M |
| Revenue growth, Y/Y | — | -55% |
| Operating margin | -583.5% | n/m |
| Net earnings | −$8.9M | −$18.5M |
| Net margin | -597.4% | — |
| Operating cash flow | −$2.7M | −$24.1M |
Where the revenue comes from
Aclaris Therapeutics
- Licensing: $1.2M (80%)
- Contract research: $300K (20%)
Questions
Which is bigger, Citius Oncology or Aclaris Therapeutics?
Citius Oncology is the larger company: $1.5M of revenue in its latest quarter (Q3 FY26) against $1.5M for Aclaris Therapeutics (Q3 2026).
More: Citius Oncology earnings · how Citius Oncology makes money · Aclaris Therapeutics earnings · how Aclaris Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.